BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis - BiomX (AMEX:PHGE)

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trialAn independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosingFollowing the DMC review, the study protocol will be updated, and topline results are now expect ...